273 related articles for article (PubMed ID: 10935344)
1. A case of mycosis fungoides after CD30 positive anaplastic large cell lymphoma.
Lee MW; Chi DH; Choi JH; Sung KJ; Moon KC; Koh JK
J Dermatol; 2000 Jul; 27(7):458-61. PubMed ID: 10935344
[TBL] [Abstract][Full Text] [Related]
2. Coexistence of CD30-positive anaplastic large cell lymphoma and mycosis fungoides.
Kang SK; Chang SE; Choi JH; Sung KJ; Moon KC; Koh JK
Clin Exp Dermatol; 2002 May; 27(3):212-5. PubMed ID: 12072011
[TBL] [Abstract][Full Text] [Related]
3. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?
Collins K; Gu J; Aung PP; Nagarajan P; Curry JL; Huen A; Ivan D; Prieto VG; Tetzlaff MT; Duvic M; Miranda RN; Vega F; Torres-Cabala CA
Virchows Arch; 2021 Aug; 479(2):377-383. PubMed ID: 33604757
[TBL] [Abstract][Full Text] [Related]
4. Disseminated CD8-positive, CD30-positive cutaneous lymphoproliferative eruption with overlapping features of mycosis fungoides and primary cutaneous anaplastic large cell lymphoma following remote solitary lesional presentation.
Davick JJ; Mutgi KAJ; Wanat KA; Link BK; Liu V
J Cutan Pathol; 2017 Aug; 44(8):703-712. PubMed ID: 28497585
[TBL] [Abstract][Full Text] [Related]
5. Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium.
Kadin ME; Hughey LC; Wood GS
J Am Acad Dermatol; 2014 Feb; 70(2):374-6. PubMed ID: 24438952
[No Abstract] [Full Text] [Related]
6. CD30 expression and proliferative fraction in nontransformed mycosis fungoides.
Edinger JT; Clark BZ; Pucevich BE; Geskin LJ; Swerdlow SH
Am J Surg Pathol; 2009 Dec; 33(12):1860-8. PubMed ID: 19898220
[TBL] [Abstract][Full Text] [Related]
7. The importance of differentiating between mycosis fungoides with CD30-positive large cell transformation and mycosis fungoides with coexistent primary cutaneous anaplastic large cell lymphoma.
Gao C; McCormack CJ; van der Weyden C; Twigger R; Buelens O; Lade S; Khoo C; Campbell BA; Goh M; McKelvie P; Prince HM
J Am Acad Dermatol; 2021 Jan; 84(1):185-187. PubMed ID: 32334059
[No Abstract] [Full Text] [Related]
8. Mycosis Fungoides Associated With Lesions in the Spectrum of Primary Cutaneous CD30+ Lymphoproliferative Disorders: The Same Process or 3 Coexisting Lymphomas?
Cieza-Díaz DE; Prieto-Torres L; Rodríguez-Pinilla SM; Córdoba Mascuñano R; Manso Alonso R; Machan S; Piris Pinilla MÁ; Requena Caballero L
Am J Dermatopathol; 2019 Nov; 41(11):846-850. PubMed ID: 30946099
[TBL] [Abstract][Full Text] [Related]
9. Transformation of Sézary syndrome into CD30+ anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity.
Nevet MJ; Zuckerman T; Sahar D; Bergman R
Am J Dermatopathol; 2015 Jan; 37(1):73-7. PubMed ID: 25548993
[TBL] [Abstract][Full Text] [Related]
10. Spatially Resolved Transcriptomes of CD30+-Transformed Mycosis Fungoides and Cutaneous Anaplastic Large-Cell Lymphoma.
Choi ME; Lee MY; Won CH; Chang SE; Lee MW; Lee WJ
J Invest Dermatol; 2024 Feb; 144(2):331-340.e2. PubMed ID: 37544586
[TBL] [Abstract][Full Text] [Related]
11. A case of Ki-1 positive anaplastic large cell lymphoma transformed from mycosis fungoides.
Kudo Y; Katagiri K; Ise T; Imamura Y; Takayasu S
J Dermatol; 1996 Sep; 23(9):606-13. PubMed ID: 8916660
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 Expression in Primary Cutaneous CD30-Positive Lymphoproliferative Disorders and Transformed Mycosis Fungoides.
Mitteldorf C; Robson A; Tronnier M; Pfaltz MC; Kempf W
Dermatology; 2015; 231(2):164-70. PubMed ID: 26111483
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
14. Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin.
Goyal A; Hordinsky M; Lazaryan A
Dermatol Ther; 2019 Mar; 32(2):e12835. PubMed ID: 30659762
[TBL] [Abstract][Full Text] [Related]
15. CD56 expression in a case of primary cutaneous CD30+ anaplastic large cell lymphoma.
Chang SE; Park IJ; Huh J; Choi JH; Sung KJ; Moon KC; Koh JK
Br J Dermatol; 2000 Apr; 142(4):766-70. PubMed ID: 10792229
[TBL] [Abstract][Full Text] [Related]
16. Response of CD30+ large cell lymphoma of skin to bexarotene.
Keun YK; Woodruff R; Sangueza O
Leuk Lymphoma; 2002 May; 43(5):1153-4. PubMed ID: 12148901
[TBL] [Abstract][Full Text] [Related]
17. Primary cutaneous anaplastic large cell lymphoma.
Brown RA; Fernandez-Pol S; Kim J
J Cutan Pathol; 2017 Jun; 44(6):570-577. PubMed ID: 28342276
[TBL] [Abstract][Full Text] [Related]
18. Primary cutaneous CD30(+) lymphoproliferative disorders.
Wieser I; Tetzlaff MT; Torres Cabala CA; Duvic M
J Dtsch Dermatol Ges; 2016 Aug; 14(8):767-82. PubMed ID: 27509411
[TBL] [Abstract][Full Text] [Related]
19. Differential molecular programs of cutaneous anaplastic large cell lymphoma and CD30-positive transformed mycosis fungoides.
Lai P; Liu F; Liu X; Sun J; Wang Y
Front Immunol; 2023; 14():1270365. PubMed ID: 37790936
[TBL] [Abstract][Full Text] [Related]
20. Transformation of mycosis fungoides: T-cell receptor beta gene analysis demonstrates a common clonal origin for plaque-type mycosis fungoides and CD30+ large-cell lymphoma.
Wood GS; Bahler DW; Hoppe RT; Warnke RA; Sklar JL; Levy R
J Invest Dermatol; 1993 Sep; 101(3):296-300. PubMed ID: 8396607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
